Using disease progression models as a tool to detect drug effect dr mould1, ng denman2 and s duffull3. Full text disease progression model for clinical dementia rating. Alzheimers disease progression model using disability assessment. The modeling of time course of glucose and insulin changes during prolonged treatment with oral hypoglycaemic drugs has to consider disease progression mechanisms as well as drug action. Pharmacokineticpharmacodynamic disease progression model. Pharmacokineticpharmacodynamic disease progression model 1625 fittings of the pk profiles are presented in fig. The cdr sb was also chosen for disease progression modeling in this. Disease progression describes the change of disease status over time as function of disease process and treatment effects. The data set utilized in the current analysis was downloaded on apr 11, 20. Randomized phase 2 study of obinutuzumab monotherapy in. The ebola virus disease is a severe viral haemorrhagic fever syndrome caused by ebola virus.
The model was shown to parse out the age dependence on variability and accurately predict the dose response for the hypothetical drug. For the sake of completeness, the disease and drug effect parameter estimates obtained with and without dropout were compared to assess the influence of informative dropout. Two patients treated on the dx1 schedule had disease stabilization for 12 weeks 5. Modelbased metaanalysis of progressionfree survival in. For the disease progression model, linear and nonlinear e. Kaplanmeier estimates of progressionfree and overall survival are presented in figs. Beginners tutorial modeling disease progression link to the presentation and the nonmem files used.
This disease is transmitted by direct contact with the body fluids of an infected person and objects contaminated with virus or infected animals, with a death rate close to 90% in humans. The disease progression model we used was established by subroutine advan6 with tol equal to 5 in nonmem, using the firstorder conditional estimation foce method without. Disease progressionclinical outcome model for castration. This is not feasible for a rare disease such as dmd. In a healthy subject, mechanisms of homeostasis ensure that the status s.
At sgs exprimo, we are focused on the application of quantitative, modelbased approaches at all stages of pharmaceutical development. Modeling is a program that allows model building to be performed using a population approach. Disease progression model in subjects with mild cognitive. Background the ability to predict progression of disease in patients with alzheimer disease ad would aid clinicians, improve the validation of biomarkers, and contribute to alternative study designs for ad therapies objective to test a calculated rate of initial decline prior to the first physician visit preprogression rate for its ability to predict progression during subsequent followup. A model that would use daily pro data in its entirety to predict changes in patient disease severity would therefore be valuable in assessing disease progression. Pdf using disease progression models as a tool to detect drug. Program welcome to the population approach group in europe. Development of a placebo effect model combined with a. The parameters in a markov model can be estimated by observing the time it takes patients in any state i to make a transition to another state j fully observed data. A hypothetical empirical disease model with linear progression. Predicting disease progression in patients with bicuspid. The status of a subject, such as a patient, may be represented by a numerical quantity s chan and holford 2001. Samtani,1 nandini raghavan,1 yingqi shi,1 gerald novak,2 michael farnum,3 victor lobanov,3 tim schultz,3 eric yang,3 allitia dibernardo,2 vaibhav a. Estimation of renal cell carcinoma treatment effects from.
This course makes extensive use of nonmem 7 and r, as well as the mifuns package. The objective is to develop a semimechanistic disease progression model for mild cognitive impairment mci subjects. The model suggested a possible effect of bapineuzumab exposure on dad progression, i. Indeed, the use of psa as a biomarker for disease progression is associated with a number of advantageous propertiescompared to imagingbased disease progression markersas it is easily. The model building proceeded as follows to fulfill the objectives the analysis highlighted above. The model was used to estimate disease progression for both placebotreated patients and acetylcholinesterase acheinhibitor treated patients, and factors that affected disease progression. Topics covered include for nonlinear pk models, modeling pk data with bql records, models for parentmetabolite data, models for plasma and urine pk data, indirect pkpd models, disease progression models and clinical trial simulations. Useful if the marker of disease progression has a natural limit 0 or some other value zero asymptote s 0, k prog spontaneous recovery or return to a 0 value of disease progression marker several functions used to describe exponential emax functions nonzero asymptote s 0, s ss, k prog. The final output was a graphical comparison of the predicted individual distribution of pdp with the actual outcome of each ct scan. Baseline severity is an important covariate to predict a curvilinear rate of disease progression in normal elderly, mild cognitive impairment, and ad patients. Background various authors have evaluated disease progression in alzheimers disease ad, using patient data from individual clinical studies or pooled data across various trials. Journal of pharmacokinetics and pharmacodynamics, 122014, volume 41, issue 6, pages.
But by using the disease progression model, a small, nonage stratified trial could detect a hypothetical drug effect using only 6 subjects per treatment arm. Early prediction of disease progression in small cell lung. Prediction of disease progression, treatment response and. Sharma, 1, 2 yuyan jin, 5 soonmo peter kang, 1, 2 walter m. Disease progression metaanalysis model in alzheimers. Tips for the choice of initial estimates in nonmem. Ebola model and optimal control with vaccination constraints. Pdf tips for the choice of initial estimates in nonmem. Implementing beta regression in nonmem presents difficulties since it does not provide gamma functions required by the beta distribution density function. Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia.
Furthermore, abstracts for an anonymous drug drug x will not be accepted unless the work clearly describes a new methodologynew disease model for a specific therapeutic area or similar, i. Markov models for disease progression are common in medical decision making see references below. Presented at the fourth annual bayesian biostatistics conference, houston, tx. Aims to determine if positive respiratory cultures of aspergillus species are associated with.
Disease progression implies that the disease changes with time. Effective longterm treatment of type 2 diabetes mellitus t2dm implies modification of the disease processes that cause this progressive disorder. Pkpd modeling and simulation services by sgs exprimo. A longitudinal doseresponse model for the progression of alzheimers disease, based on a combination of summarylevel and patientlevel data. Nonmem nonlinear mixed effects modeling is a program that allows model building to be. Disease progression of pc can be monitored by measuring the serum levels of prostatespecific antigen psa, which have been associated with survival. The solid line represents disease progression with no treatment, and the other lines represent disease progression with treatment effects that start at time 12 and end at time 48. The full program and all abstracts can be downloaded as a single word document here. Pro data generally reflect health status reports that come directly from the patient and are being increasingly used to inform clinical decisions and assess improvements in a patient. Beta regression models have been recommended for continuous bounded outcome scores that are often collected in clinical studies.
Disease progression models were established using nonmem version 7. Estimation of renal cell carcinoma treatment effects from disease progression modeling michael l. The objective of the study was to implement mixedeffects beta regression models in nonmem using nemes. Summarylevel pfs was obtained from 112 of these trials, which included 155 cohorts and 11,824 patients. Pkpd modeling and simulation services life sciences sgs. Linear, e max, and sigmoidal e max models were tested. The outcome of the study was progression to advanced chronic kidney disease, defined as a sustained outpatient egfr value of less than 30 mlmin1. Osteoarthritis disease progression model using six year. A disease progression model was previously developed for patients with ad, 14 and since the mci population represents a distinctly different sub. The disease status changes with time, therefore modelling of the disease status in the absence of treatment describes the expected changes in patients disease progression. Pdf population pharmacokineticpharmacodynamicdisease. A beta regression logistic model best described disease progression as measured by dad scores for patients with mildtomoderate ad in studies 301 and 302. The models for disease progression, drug effects and dropout were developed simultaneously. Using disease progression models as a tool to detect drug effect.
Studying the critical transitional phase between healthy to overtly diabetic in type 2 diabetes mellitus t2dm is of interest, but acquiring such clinical data is impractical due to ethical concerns and would require a long study duration. Application of item response theory to modeling of. Multistate markov models for disease progression with. Rehg college of computing georgia institute of technology atlanta, ga abstract the continuoustime hidden markov model cthmm is an attractive approach to modeling disease progression due to its ability. A method for estimating progression rates in alzheimer disease. Clinical pharmacology is not a static description of the use of a drug but includes. At any given point of time, the status of the patient is a reflection of the status of the disease. Disease progression model in subjects with mild cognitive impairment from the alzheimers disease neuroimaging initiative. Disease progression model for clinical dementia ratingsum. Pfs was measured from the time of randomization to disease progression. A population pharmacokineticpharmacodynamicdisease progression pkpddis model was developed to characterize the effects of anakinra in collageninduced arthritic cia rats and explore. Predicting risk of advanced chronic kidney disease after. Disease progression modeling analysis of the change of.
This represents a series of successively more severe stages of disease and an absorbing state, often death. Frequently, however, what is recorded is the starting state and the endstate t years later, without information. University of groningen translational pkpd modeling in. The solid line represents disease progression with no treatment, and the other lines represent disease progression with treatment effects. The implementation of modelbased approaches in drug development helps to bring new, safe and effective medicines to patients more efficiently.
Survival at 6 months was 45% for patients on dx1 and 29% on the dx5 schedule. Two online nonmem courses may 11 and 1415 andrew hooker sat mar 28 2020 06. Csf biomarkers predict population subtypes mahesh n. Disease progression models were established using extended least squares regression by nonmem version 7. Drug action refers to the time course of drug effect and includes pharmacokinetics, pharmacodynamics and a link model to account for delays in effect in relation to drug concentration. Mixedeffects beta regression for modeling continuous. Methods we collected 576 mean adascog changes from baseline data points of 52 trials, representing data from approximately 19,972 patients and more than. Disease progression model for clinical dementia ratingsum of boxes in mild cognitive impairment and alzheimers subjects from the alzheimers disease neuroimaging initiative mahesh n samtani, nandini raghavan, gerald novak, partha nandy, vaibhav a narayan on behalf of the alzheimers disease neuroimaging initiative janssen research and development, llc, raritan, new jersey, usa. Characteristics evaluated for their impact on pfs included cohort treatment, percentage of patients with each nhl subtype, percentage of patients with different numbers of prior treatments. To develop a disease progression model that describes the time course of acrn in ra. Recently, some mathematical models have been presented to analyse the spread of the 2014 ebola outbreak in west. Background the impact of aspergillus on lung disease in young children with cystic fibrosis is uncertain. Disease progression model for cognitive deterioration from.
A disease progression model adequately described the natural decline of adascog observed in alzheimers disease neuroimaging initiative. Mathematical modeling was undertaken to assess 1 the nonlinearity associated with the disease progression and 2 the importance of. A novel method for analysing frequent observations from. Markov disease progression models bristol medical school. The model aims to describe the longitudinal progression of adascog scores from the alzheimers disease neuroimaging initiative trial that had data from 198 mci subjects with cerebrospinal fluid csf information who were followed for 3 years. This was achieved by applying the framework detailed in the next section individual early prediction of disease progression but modified to use all data available i.
Bicuspid as patients who underwent at least two serial echocardiograms from 2005 to 2017 were enrolled. Alzheimers disease progression model using disability. A mathematical model to describe the disease progression of osteoarthritis in the studied population was developed. Using disease progression models as a tool to detect drug. Moreover, they gave insight into disease progression of rrms.
A database was developed from 5 nhl clinical trials reported from 1993 to 2015. Placebo effects clinical pharmacology outline disease. Mould has also provided example code for implementing such models in nonmem software 12. We aimed to develop a mathematical model to predict the progression of aortic stenosis as and aortic dilatation ad in bicuspid aortic valve patients. More complex effects based on turnover models have been described in post tm, freijer ji, dejongh j, danhof m.
285 466 843 1480 1256 1158 1148 226 491 8 223 680 443 706 1485 452 1055 192 133 554 1276 418 502 508 21 1160 1362 438 342 647 192 273 1495 1059 508 516 703 1224 1266 479 652 57 108 55